› $150,000,000 verdict in personal injury case
Wyeth Pharmaceuticals has lost its appeal to the Supreme Court of Pennsylvania in 14 consolidated cases alleging that its hormone replacement therapy (HRT) drugs had caused breast cancer. Trial lawyers say the decision, which makes the discovery rule an issue of fact for the jury, will likely affect the 15,000 HRT cases pending in lower court.
For years, Mrs. Smith* chose not to take hormone replacement therapy (HRT) to treat bothersome symptoms of menopause. During menopause, some women become “estrogen deficient” – their estrogen level drops so low that they experience symptoms such as hot flashes, night sweats and vaginal dryness that can be so severe it interferes with a woman’s quality of life.
Mrs. Smith talked to her doctor, who recommended Prempro, a pill made by Wyeth that contains a mixture of estrogen and synthetic progestin hormones. The pills were also marketed to doctors and women as a miracle drug that tamed not only menopausal symptoms but also had the added benefit of protecting women against heart disease and osteoporosis. HRT became widely prescribed, and Wyeth racked in billions in profits.
The reports of health problems associated with hormone replacement therapy (HRT) keep coming. First, the Women’s Health Initiative identified women who took the combined estrogen-plus-progestin therapy were at a much greater risk of developing breast cancer. It later showed these women were at an increased risk of heart disease and other serious health problems. Now, an article published online in the Journal of Clinical Oncology suggests that women who took combined HRT are at an increased risk of lung cancer by as much as 50 percent.
William T. Creasman was listed as the author of an article written by a freelance writer for the December 1998 Journal of Women’s Health. The title: “Is there an association between hormone replacement therapy and breast cancer?” The article points out that there is no “definitive evidence” that HRT is linked to breast cancer. But the dirty little secret behind that article in the medical journal is that Creasman didn’t actually write the article. It was authored by a writer for DesignWrite, a marketing firm that represented HRT-maker Wyeth, now owned by Pfizer. As the story was going to press, Wyeth was covering up evidence that proved otherwise. The drug company’s estrogen-plus-progestin HRT was, in fact, increasing a woman’s risk for breast cancer as well as heart disease and Alzheimer’s.
Drug companies’ advertisements touting the benefits of hormone replacement therapy (HRT) sold Delores Ann Spann Whatley of Tyler, Texas on the idea that her mood swings and hot flashes could be wiped away with just a daily pill. The estrogen-and-progestin cocktail was touted as a miracle drug, able to squash menopause symptoms while warding against osteoporosis, heart disease and cancer. But the pharmaceutical companies soon realized that the HRT that was making them rich was actually making consumers sick. But instead of notifying the public and pulling their product, the drug companies attempted to cover up the mounting statistics and continued to advertise to women about the benefits of HRT.
Women who reported new-onset breast tenderness following use of estrogen-plus-progestin hormone replacement therapy (HRT) were at a much greater risk of developing breast cancer than women on the same HRT who did not report tenderness in their breasts, according to a study by researchers from the David Geffen School of Medicine at the University of California – Los Angeles.
The advertisements no longer blanket magazines or fill television screens, but the message cannot be deleted. Over the years, millions of women were told that estrogen loss during menopause could be dangerous to their health, contributing to problems such as osteoporosis, heart disease, colon cancer, Alzheimer’s disease, tooth loss and blindness. It could also cause uncomfortable symptoms such as hot flashes, vaginal dryness and mood swings. The ads said menopause was a nasty disease that could be eliminated by just taking a once-daily pill, a hormone replacement therapy (HRT) that would help women feel like women again.
The message was heard loud and clear – powerful drug companies that make billions from products they know pose a significant risk of life-threatening health consequences to the people who take them, owe their victims. Big time.
This week, Pfizer, which recently acquired Wyeth, the makers of the hormone replacement therapies (HRT) Prempro and Premarin, were hit with more than $100 million in two punitive-damage awards from Philadelphia juries. The two plaintiffs, Connie Barton and Donna Kendall, claimed the drugs caused their breast cancer.
Drug maker Wyeth paid ghostwriters to write articles for medical journals that were favorable to the company’s hormone replacement therapy (HRT) Prempro , even after the drug was found to raise a woman’s risk for breast cancer and other serious health concerns, according to newly unveiled court documents. Medical journals such as The American Journal of Obstetrics and Gynecology and The International Journal of Cardiology name doctors as authors of articles that typically involve heavily research topics and offer a judgment on how to treat a particular condition. It is believed that doctors are often swayed by those published opinions and may be influenced by them when prescribing medication to their patients.
Use of hormone replacement therapy (HRT) among postmenopausal women has been linked to a sharply increased risk of ovarian cancer, according to a study conducted by a team of researchers in Denmark. The study included data from 900,000 Danish women ages 50 to 79 over eight years and found 140 extra cases of ovarian cancer – or a 38 percent greater risk of contracting the disease compared to women who did not use HRT.
